Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy

被引:2
|
作者
Hu, Zhongjie [1 ]
Liu, Ying [2 ]
Qiu, Lixia [1 ]
Fan, Zuopeng [1 ]
Nie, Wei [1 ]
Liang, Shan [1 ]
Jin, Ronghua [3 ]
机构
[1] Capital Med Univ, Beijing Youan Hosp, Dept Hepatitis & Tox Liver Dis C, Beijing 100069, Peoples R China
[2] Capital Med Univ, Beijing Youan Hosp, Management Ctr Med Record, Beijing 100069, Peoples R China
[3] Capital Med Univ, Beijing Youan Hosp, Beijing 100069, Peoples R China
关键词
Hepatitis C virus; Genotype; 1b; Amino acid 70 substitution; Interferon; Viral kinetics; HEPATITIS-C VIRUS; AMINO-ACID SUBSTITUTIONS; VIROLOGICAL RESPONSE; JAPANESE PATIENTS; COMBINATION THERAPY; INHIBITS INTERFERON; PREDICTIVE FACTORS; GENETIC-VARIATION; NON-A; PROTEIN;
D O I
10.1186/s12985-015-0451-9
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-alpha plus ribavirin combination therapy (PEG-IFN alpha/RBV). But the exact mechanisms remain unclear. The aim of this study was to investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFN alpha/RBV treatment. Methods: One hundred twelve Chinese patients with chronic HCV 1b infection were enrolled and received a standard protocol of 48 weeks of PEG-IFN alpha/RBV therapy and 24 consecutive weeks of follow-up. Serial blood samples were obtained at pretreatment baseline, and again at weeks 2, 4, 8, 12, and 24 during therapy for the quantification of 70R and 70Q/H strains. Dynamic characteristics and association with early virological response (EVR), sustained virological response (SVR) and IL28B genotypes were analyzed. Results: Of the 112 patients enrolled in this study, 93.8 % (105/112) were infected with mixture of 70R and 70Q/H strains before treatment. The 70Q/H strain was dominant in 20.5 % of patients. 42.9 % of patients with dominant 70Q/H exhibited EVR versus 88.6 % of patients with dominant 70R (P < 0.001). Furthermore, 35.0 % of patients with dominant 70Q/H exhibited SVR versus 77.4 % with dominant 70R (P < 0.001). However, regardless of the dominant strain, virological response types or the IL28B SNP genotypes, 70Q/H strains always exhibited the same response to treatment as the 70R strains and the percentage of HCV harboring the 70Q/H substitution did not change significantly during treatment. Conclusions: Although the ratio of 70Q/H to 70R is related to the virological response, 70Q/H strains always exhibited the same response as the 70R strains during PEG-IFN alpha/RBV treatment. Substitution of R70Q/H alone is not enough to lead to resistance to therapy. Positive selection for 70Q/H induced by IFN alpha was not observed.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks
    Suzuki, Fumitaka
    Akuta, Norio
    Suzuki, Yoshiyuki
    Sezaki, Hitomi
    Yatsuji, Hiromi
    Kawamura, Yusuke
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Arase, Yasuji
    Ikeda, Kenji
    Mineta, Rie
    Iwasaki, Satomi
    Watahiki, Sachiyo
    Kobayashi, Mariko
    Miyakawa, Yuzo
    Kumada, Hiromitsu
    HEPATOLOGY RESEARCH, 2009, 39 (11) : 1056 - 1063
  • [32] Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients
    de Castellarnau, Montserrat
    Aparicio, Ester
    Parera, Mariona
    Franco, Sandra
    Tural, Cristina
    Clotet, Bonaventura
    Angel Martinez, Miguel
    PLOS ONE, 2012, 7 (02):
  • [33] Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy
    Kumthip, K.
    Pantip, C.
    Chusri, P.
    Thongsawat, S.
    Brien, A. O.
    Nelson, K. E.
    Maneekarn, N.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (04) : e117 - e125
  • [34] IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C
    Chayama, Kazuaki
    Hayes, C. Nelson
    Abe, Hiromi
    Miki, Daiki
    Ochi, Hidenori
    Karino, Yoshiyasu
    Toyota, Joji
    Nakamura, Yusuke
    Kamatani, Naoyuki
    Sezaki, Hitomi
    Kobayashi, Mariko
    Akuta, Norio
    Suzuki, Fumitaka
    Kumada, Hiromitsu
    JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (01) : 84 - 93
  • [35] Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin
    Yang, SS
    Lai, MY
    Chen, DS
    Chen, GH
    Kao, JH
    LIVER INTERNATIONAL, 2003, 23 (06): : 426 - 433
  • [36] Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation
    Fukuhara, Takasuke
    Taketomi, Akinobu
    Okano, Shinji
    Ikegami, Toru
    Soejima, Yuji
    Shirabe, Ken
    Maehara, Yoshihiko
    JOURNAL OF HEPATOLOGY, 2010, 52 (05) : 672 - 680
  • [37] Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon α-2b to α-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report
    Kawaoka, Tomokazu
    Hiraga, Nobuhiko
    Takahashi, Shoichi
    Takaki, Shintaro
    Tsuge, Masataka
    Nagaoki, Yuko
    Hashimoto, Yoshimasa
    Katamura, Yoshio
    Miki, Daiki
    Hiramatsu, Akira
    Waki, Koji
    Imamura, Michio
    Kawakami, Yoshiiku
    Aikata, Hiroshi
    Ochi, Hidenori
    Tashiro, Hirotaka
    Ohdan, Hideki
    Chayama, Kazuaki
    INTERVIROLOGY, 2012, 55 (04) : 306 - 310
  • [38] Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load
    Tamai, Hideyuki
    Mori, Yoshiyuki
    Shingaki, Naoki
    Kawashima, Akira
    Tsukuda, Hiroshi
    Higashi, Katsuhiko
    Moribata, Kosaku
    Kawaguchi, Masanori
    Ueda, Kazuki
    Deguchi, Hisanobu
    Inoue, Izumi
    Maekita, Takao
    Iguchi, Mikitaka
    Kato, Jun
    Ichinose, Masao
    ANTIVIRAL THERAPY, 2014, 19 (01) : 107 - 115
  • [39] Recurrent hepatitis C genotype 1b following liver transplantation:: treatment with combination interferon-ribavirin therapy
    Berenguer, M
    Prieto, M
    Palau, A
    Carrasco, D
    Rayón, JM
    Calvo, F
    Berenguer, J
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (11) : 1207 - 1212
  • [40] Biochemical response to interferon therapy correlates with interferon sensitivity-determining region in hepatitis C virus genotype 1b infection
    Yoshioka, K
    Kobayashi, M
    Orito, E
    Watanabe, K
    Yano, M
    Sameshima, Y
    Kusakabe, A
    Hirofuji, H
    Fuji, A
    Kuriki, J
    Arao, M
    Murase, K
    Mizokami, M
    Kakumu, S
    JOURNAL OF VIRAL HEPATITIS, 2001, 8 (06) : 421 - 429